Unlike centrosome declustering-based treatment strategies (such as the use of KIFC1 inhibitors) that cripple centrosome clustering mechanisms but spare pathways that continue to generate excess centrosomes, pharmacological targeting of FOXM1 would simultaneously disable both evils that help cancer cells flourish. This evidence concerns the gene FOXM1 and cancer.